根据 HR+/HER2-乳腺癌患者更年期状况的组织病理特征和复发率得分之间的相关性:一项回顾性研究
Federica Martorana1,2, Sabrina Nucera1,2, Gianmarco Motta1,2
1Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Exploration of targeted anti-tumor therapy
|July 28, 2025
概括
组织病理特征与基于更年期状态的乳腺癌复发率得分有不同的相关性. 了解这些变异对于完善早期激素受体阳性,HER2阴性乳腺癌患者的风险分层是关键.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 病理学 病理学 病理学
背景情况:
- 传统上,临床病理特征指导乳腺癌 (BC) 预后和辅助治疗.
- 像Oncotype DX这样的基因组测试完善了激素受体阳性 (HR+) /人体表皮生长因子受体2阴性 (HER2-) BC患者的风险分层.
- 更年期状态是BC的一个关键因素,可能会影响治疗反应和预后.
研究的目的:
- 对HR+/HER2-早期BC患者的组织病理学参数和复发率 (RS) 之间的相关性进行调查.
- 分析这些相关性,同时考虑更年期状态 (更年期前与更年期后).
- 确定在不同更年期组中预测RS的特定临床病理因素.
主要方法:
- 对180名HR+/HER2-早期BC患者进行回顾性分析,这些患者接受了型DX测试.
- 收集的临床病理学数据包括瘤等级 (G3),Ki67,雌激素受体 (ER%) 和孕激素受体 (PgR%).
- 使用连续RS的线性回归和二分化RS的逻辑回归 (16和25的值),按更年期状态分层.
主要成果:
- 整体队列显示了与G3,Ki67%,ER%和PgR%的显著RS相关性.
- 在绝经前的患者中,Ki67%,ER%和PgR%与RS显著相关;PgR%预测RS>16.
- 在绝经后的患者中,G3,Ki67%和PgR%显著相关;Ki67%和PgR%预测RS>25.
结论:
- 临床病理特征与RS呈现不同的相关性,这取决于HR+/HER2-早期BC的绝经状态.
- 这些发现强调了风险分层的复杂性和个性化方法的必要性.
- 需要进一步的研究,以充分阐明影响RS的因素,并优化其在不同患者群体中的临床效用.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
289
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
289
01:21Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
01:28Menopause
251
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
251
01:12Hazard Ratio
251
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
251